HK Stock Market Move | China Overseas Land & Investment Ltd. (00081) fell by over 5% in the afternoon, with annual net profit dropping by 68.07% year-on-year. The final dividend was reduced to 2.5 Hong Kong cents.
China Overseas Grand Oceans Group (00081) fell more than 5% in the afternoon, dropping by 5.06% to HK$2.25 as of the time of writing, with a turnover of HK$13.8279 million.
CH OVS G OCEANS (00081) fell more than 5% in the afternoon, dropping 5.06% to HK$2.25 at the time of writing, with a turnover of HK$1382.79 million.
On the news front, CH OVS G OCEANS released its annual results for the year ending December 31, 2025. The group achieved revenue of HK$36.874 billion, a 19.66% decrease year-on-year; the attributable profit to owners of the company was HK$305 million, a 68.07% decrease year-on-year; and earnings per share were 8.6 cents. In addition, the board of directors proposed a final dividend of 2.5 HK cents per share for the year 2025, a 64.29% decrease year-on-year. Taking into account the interim dividend of 1 HK cent per share already paid out for 2025, the total dividend for the year will be 3.5 HK cents per share, a 65% decrease year-on-year. The total dividend payout ratio for the year is approximately 36.0%.
Related Articles

PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc

HK Stock Market Move | Bitcoin has fallen by nearly 10% in the past month, LINEKONG (08267) has dropped more than 12%, and GOLDSTREAM INV (01328) has fallen by almost 11%.

Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.
PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc

HK Stock Market Move | Bitcoin has fallen by nearly 10% in the past month, LINEKONG (08267) has dropped more than 12%, and GOLDSTREAM INV (01328) has fallen by almost 11%.

Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.






